Keith Pietropaolo
About
In The Last Decade
Keith Pietropaolo
28 papers receiving 343 citations
Peers
Comparison fields: 5 of 49
- Infectious Diseases 211
- Hepatology 194
- Epidemiology 190
- Molecular Biology 67
- Organic Chemistry 34
Countries citing papers authored by Keith Pietropaolo
This map shows the geographic impact of Keith Pietropaolo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keith Pietropaolo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keith Pietropaolo more than expected).
Fields of papers citing papers by Keith Pietropaolo
This network shows the impact of papers produced by Keith Pietropaolo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keith Pietropaolo. The network helps show where Keith Pietropaolo may publish in the future.
Co-authorship network of co-authors of Keith Pietropaolo
This figure shows the co-authorship network connecting the top 25 collaborators of Keith Pietropaolo. A scholar is included among the top collaborators of Keith Pietropaolo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keith Pietropaolo. Keith Pietropaolo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 1 | |
| 3 | 6 | |
| 4 | 1 | |
| 5 | 7 | |
| 6 | 5 | |
| 7 | High lung levels of active triphosphate predicted with oral at-527 in COVID patients | 1 |
| 8 | 36 | |
| 9 | 25 | |
| 10 | 9 | |
| 11 | 11 | |
| 12 | 5 | |
| 13 | 50 | |
| 14 | 18 | |
| 15 | 10 | |
| 16 | 34 | |
| 17 | 17 | |
| 18 | 27 | |
| 19 | Phase Iib Extended-Treatment Trial of Telbivudine (LdT) Vs Lamivudine Vs Combination Treatment in Hepatitis B Patients: Two-Year Results | 12 |
| 20 | Valtorcitabine provides potent suppression of hepatitis B virus in patients with chronic hepatitis B: Results of a phase I/II clinical trial | 3 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.